Verastem (VSTM) Other Non-Current Liabilities (2012 - 2025)
Verastem (VSTM) posted quarterly Other Non-Current Liabilities of $35.6 million for Q4 2025, down 38.75% year-over-year from $58.2 million in Q4 2024, and down 26.18% quarter-over-quarter from $48.3 million in Q3 2025.
Analysis
Verastem (VSTM) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Verastem's Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $35.6 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 38.75% year-over-year to $35.6 million; the TTM figure through Dec 2025 stood at $35.6 million (down 38.75% YoY), while the FY2025 annual figure was $35.6 million, down 38.75% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $35.6 million, down from $48.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $58.2 million in Q4 2024, with the low at $51000.0 in Q3 2023.
- The 3-year median for Other Non-Current Liabilities is $35.6 million (2025), against an average of $32.9 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 51150.98% in 2024, then plunged 38.75% in 2025.
- Verastem's Other Non-Current Liabilities stood at $51000.0 in 2023, then surged by 114015.69% to $58.2 million in 2024, then plunged by 38.75% to $35.6 million in 2025.
- Business Quant data shows VSTM's Other Non-Current Liabilities at $35.6 million in Q4 2025, $48.3 million in Q3 2025, and $7.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 35.65 Mn |
| Sep 30, 2025 | 48.29 Mn |
| Jun 30, 2025 | 21.76 Mn |
| Mar 31, 2025 | 54.75 Mn |
| Dec 31, 2024 | 58.20 Mn |
| Sep 30, 2024 | 26.14 Mn |
| Sep 30, 2023 | 51,000.00 |
| Jun 30, 2020 | 870,000.00 |
| Mar 31, 2020 | 870,000.00 |
| Dec 31, 2019 | 870,000.00 |
| Sep 30, 2019 | 870,000.00 |
| Jun 30, 2019 | 500,000.00 |
| Mar 31, 2019 | 500,000.00 |
| Dec 31, 2018 | 1.12 Mn |
| Sep 30, 2018 | 566,000.00 |
| Jun 30, 2018 | 399,000.00 |
| Mar 31, 2018 | 101,000.00 |
| Dec 31, 2017 | 151,000.00 |
| Sep 30, 2017 | 201,000.00 |
| Jun 30, 2017 | 248,000.00 |